Navigation Links
NIH launches trial to evaluate anti-inflammatory treatment for preventing heart attacks, strokes, and cardiovascular deaths
Date:8/21/2012

An international multi-site trial has launched to determine whether a common anti-inflammatory drug can reduce heart attacks, strokes, and deaths due to cardiovascular disease in people at high risk for them. This study is being supported by the National Heart, Lung, and Blood Institute (NHLBI), a part of the National Institutes of Health.

Inflammation, along with high blood pressure and high cholesterol, plays a major role in heart attack and stroke. The Cardiovascular Inflammation Reduction Trial (CIRT) will determine whether treatment with a drug specifically targeting inflammation reduces rates of cardiovascular events among adults who have had a heart attack within the past five years and who also have type 2 diabetes or metabolic syndrome. The trial will randomly assign participants to receive methotrexate given at 10 to 20 milligrams weekly for three to four years or a placebo. Methotrexate is an inexpensive generic drug commonly used at low doses to treat rheumatoid arthritis. It is also used at higher doses to treat certain forms of cancers such as leukemias and lymphomas.

"This trial could have global impact by potentially changing treatment recommendations for millions of individuals with heart disease," said Gary H. Gibbons, M.D., director of the NHLBI.

Each year, over 2 million people in the United States have heart attacks or strokes, and many of them die. "If this generic drug, which is already on the market at low cost, proves effective for reducing risk of heart attacks, stroke, or death, it has the potential for broad public health impact in saving lives and reducing disease," said Paul Ridker, M.D., M.P.H., an expert in inflammation biology as it relates to heart attack and stroke. Dr. Ridker, who will serve as principal investigator for CIRT, is the Eugene Braunwald Professor of Medicine at Harvard Medical School, and director of the Center for Cardiovascular Disease Prevention at the Brigham and Women's Ho
'/>"/>

Contact: NHLBI
NHLBI_news@nhlbi.nih.gov
301-496-4236
NIH/National Heart, Lung and Blood Institute
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Dallas Launches Insecticide Spraying Against West Nile Virus
2. Elsevier launches new journal: Performance Enhancement & Health
3. American Chemical Society launches 2012 edition of popular Prized Science video series
4. ASH launches multi-million-dollar grant program to support critical blood disease research
5. Oxford University Press launches Evolution, Medicine, and Public Health
6. Northwestern launches comprehensive program for patients with bicuspid aortic valve disease
7. LaStone Launches Merger with TIR Massage Stone To Further The Advancement of Massage Therapy Education in 2012
8. Washington Massage School Launches Private Practice Clinic
9. beyondblue Launches Depression & Anxiety website and Info Line for Men
10. Amirsys AnatomyOne Launches Today
11. Friends Life Care, a Pennsylvania Based Long-Term Care Provider, Launches VigR eMeetinghouse — An Interactive Online Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Sept. 18, 2014 (HealthDay News) -- Rising temperatures in ... to spread to shallow waters that are becoming warmer, ... coral reefs, ecologists report. A study of 40 ... shows northward movement by the invasive and poisonous lionfish, ... Administration (NOAA) and the University of North Carolina-Wilmington, who ...
(Date:9/18/2014)... HealthDay Reporter , THURSDAY, Sept. 18, ... in West Africa is starting to spread faster than ever, the ... of the deadly viral infection were reported in just one week. ... 5,300, with roughly half of those reported in the past three ... now tops 2,600. WHO has estimated that as many as ...
(Date:9/18/2014)... 18, 2014 Limited spots remain at ... Only 100 spots are still available for Becker's ASC ... ASCs on October 23-25, 2014 at the Swissotel Chicago. ... Chief Information Officer Strategy Roundtable on November 4, 2014 ... remain for Becker's Hospital Review Chief Executive Officer Strategy ...
(Date:9/18/2014)... One of the most capable and ... ShandsCair Flight Program’s new EC155 B1, will ... at the Air Medical Transport Conference (AMTC), Sept. 22-24, ... into service ShandsCair EC155 and the Vanderbilt University ... AMTC highlight Airbus Helicopters broad, industry leading line-up of ...
(Date:9/18/2014)... 18, 2014 It is that time of ... and wellness. Once again, Evensong Spa at ... offering three services at a special $50 rate Oct. 20 ... Marcus Hotels & Resorts , is the only Wisconsin ... Americans to embrace health and wellness by experiencing affordable spa ...
Breaking Medicine News(10 mins):Health News:Rising Atlantic Ocean Temperatures Could Pose Threat to Reefs 2Health News:New Ebola Cases Top 700 in Just One Week, Officials Report 2Health News:New Ebola Cases Top 700 in Just One Week, Officials Report 3Health News:Limited Spots Remain at Becker's Upcoming ASC and Hospital Conferences 2Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 2Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 3Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 4Health News:Evensong Spa Celebrates Spa Week with $50 Services 2Health News:Evensong Spa Celebrates Spa Week with $50 Services 3
... drugs, promising drug candidates must pass toxicity tests before ... and Whitehead Institute have developed a cell culture ... prove dramatically cheaper than existing animal tests. This assay ... in the drug development process, making it much more ...
... been able to identify neural signatures of effective, ... and analyze both behavior and brain activity ... a specially designed dual-electroencephalogram (EEG) and the conceptual ... study, The Phi Complex as a Neuromarker of ...
... on schedule to become one of the first major universities ... from its campus. University officials intend to give the ... to adjust to the policy: the ban is scheduled to ... is a health issue, said Mary Alice Serafini, assistant vice ...
... Cancer Institute at Princess Margaret Hospital have successfully proven that ... drug that is triggered by a laser light, a ... a study published today in the Proceedings of the National ... Division of Biophysics and Bioimaging, Joey and Toby Tanenbaum/Brazilian Ball ...
... (Childrens Hospital Boston) and colleagues have identified the cancer ... of childhood. ,'Identifying the cancer stem ... in ERMS will likely lead to new insights into ... explains Dr. Zon. ,Rhabdomyosarcoma (RMS) is an ...
... Rsearchers at the University of Florida, found that self-confidence ... more over a lifetime. Believing in yourself ... the study found. ,People with high opinions ... salaries in middle age than their less confident counterparts, ...
Cached Medicine News:Health News:DNA-damage Test Could Aid Drug Development 2Health News:DNA-damage Test Could Aid Drug Development 3Health News:New Brain Neuromarker May Shed Light on Autism and Schizophrenia 2Health News:New Brain Neuromarker May Shed Light on Autism and Schizophrenia 3Health News:University of Arkansas to Ban Tobacco from Its Campus 2Health News:University of Arkansas to Ban Tobacco from Its Campus 3Health News:Scientists Activate New Cancer Drug Using Light and Oxygen 2Health News:Pediatric Cancer Stem Cell Identified 2Health News:Teenage Self Confidence Can Translate Later into Material Wealth 2Health News:Teenage Self Confidence Can Translate Later into Material Wealth 3
(Date:9/18/2014)...  PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results ... June 30, 2014. Quarter Ended June ... 30, 2014 increased $492,000, or 18%, to $3.2 million ... 30, 2013, due primarily to an increase of $746,000 ... Company,s largest customer, partially offset by an aggregate decrease ...
(Date:9/18/2014)... Texas , Sept. 18, 2014  Casen Buswell has ... and muscles to harden.  His case is one of only ... the world.  The only hospital in the United ... the world, offering treatment with the dual wave-length laser, is ... San Antonio . Using a laser available in ...
(Date:9/18/2014)... PHILADELPHIA and LONDON ... new era for biopharmaceutical companies. Competition for innovation, ... necessity to keep up with the fast-changing environment ... also influence clinical trials, and clinical trial costs ... effective patient recruitment. Studies conducted by ...
Breaking Medicine Technology:Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 2Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 3Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 4Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 5Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 6Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 7Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 8Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 9Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 10Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 11Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 12Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 13Methodist Children's Hospital In San Antonio, TX Only Hospital In The U.S. Treating Rare Vascular Condition With Dual Wave-Length Laser 2Patient Recruitment in Asia Biotech and Pharma Companies 2Patient Recruitment in Asia Biotech and Pharma Companies 3
... from a Phase III,clinical trial evaluating the efficacy ... the treatment of postmenopausal osteoporosis were,presented at the ... Annual Meeting. In the non-inferiority study comparing risedronate ... [Actonel(R) (risedronate sodium,tablets)] increases in bone mineral density ...
... Medical,Technologies, Inc. (Nasdaq: RMTI ), a ... specialty pharmaceuticals focused on the end-,stage-renal-disease market ... in its Phase IIb dose-ranging study for ... drug. The Phase IIb dose-ranging study ...
Cached Medicine Technology:New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 2New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 3New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 4New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 5New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 6Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 2Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 3Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: